The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

The present invention provides a novel antibody format that does not use hetero-association technology and that is theoretically free of by-products having immune activity. This multispecific antibody has a Fab region that includes one polypeptide a chain and two polypeptide b chains. The polypeptide a chain includes a polypeptide in which a variable region Va1, a stationary region Ca1, a peptide linker LL, a variable region Va2 and a stationary region Ca are linked in the stated order. The polypeptide b chain includes a polypeptide in which a variable region Vb is linked to a stationary region Cb, which is linked to the stationary region Ca1 or the stationary region Ca2.

The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.

This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1 (e.g. cancer).

A fusion protein comprises a first nanocage monomer subunit of a nanocage monomer; and a bioactive moiety linked to the first nanocage monomer subunit; wherein the fusion protein self-assembles with a protein comprising a second nanocage monomer subunit to form a nanocage monomer.

Isolated or recombinant EphA5 or GRP78 targeting antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. A method of rapidly identifying antibodies or antibody fragments for the treatment of cancer using a combination of in vitro and in vivo methodologies is also provided.

The present invention relates to bispecific or biparatopic antigen binding proteins, polynucleotides encoding the same, and methods of making bispecific or biparatopic antigen binding proteins. Also described herein is a method to assemble IgG-like biparatopic or bispecific antibodies from VH only antigen binding proteins.

The present disclosure relates to an improved method for the manufacture of polypeptides comprising at least three or at least four immunoglobulin single variable domains (ISVDs). More specifically, an improved method is provided of producing, purifying and isolating polypeptides comprising at least three or at least four ISVDs in which an undesired product-related conformational variant is reduced or absent.

The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 (CEA) and human CD3ε. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases.

The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.